Maravai LifeSciences Holdings Inc (MRVI)
7.665
-0.06
(-0.71%)
USD |
NASDAQ |
Apr 24, 16:00
7.675
+0.01
(+0.13%)
After-Hours: 20:00
Maravai LifeSciences Holdings Research and Development Expense (Quarterly): 4.594M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 4.594M |
| September 30, 2023 | 4.347M |
| June 30, 2023 | 4.194M |
| March 31, 2023 | 4.145M |
| December 31, 2022 | 5.011M |
| September 30, 2022 | 5.389M |
| June 30, 2022 | 4.274M |
| March 31, 2022 | 3.695M |
| December 31, 2021 | 9.184M |
| Date | Value |
|---|---|
| September 30, 2021 | 1.946M |
| June 30, 2021 | 1.929M |
| March 31, 2021 | 2.16M |
| December 31, 2020 | 2.092M |
| September 30, 2020 | 1.868M |
| June 30, 2020 | 1.60M |
| March 31, 2020 | 3.744M |
| December 31, 2019 | 0.979M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.979M
Minimum
Dec 2019
9.184M
Maximum
Dec 2021
3.597M
Average
3.744M
Median
Mar 2020
Research and Development Expense (Quarterly) Benchmarks
| ModivCare Inc | -- |
| Dyadic International Inc | 0.8528M |
| Enveric Biosciences Inc | 1.369M |
| Monopar Therapeutics Inc | 1.036M |
| SeaStar Medical Holding Corp | 1.075M |